

EANO2023

IMPROVING PATIENT CARE: NEW PERSPECTIVES ON HDMTX TREATMENT IN NEURO-ONCOLOGY

Chairman: Dr Scott Howard (USA)

Friday, September 22nd
13:15-14:15 (CET)

De Doelen ICC Rotterdam
Van Weelde Zaal
Parallel hall 2

1 HDMTX: a Cornerstone in Neuro-Oncology

Dr Scott Howard (USA)



2 Maximising Patient Care: Examples from the EU Registry

Dr Madhumita Dandapani (UK)



3 Strategies to Improve HDMTX Outcomes: Updates from the METHOGLU Study

Dr Caroline Houillier (France)



4 Summary, Practical Advice, and Audience Questions

All speakers

EANO2023



Dr Scott Howard

Scott Howard, MD MSc trained in internal medicine, pediatrics, and epidemiology at the University of Tennessee and completed his hematology/oncology fellowship at St. Jude Children's Research Hospital. After his fellowship, he served as a St. Jude faculty member for 14 years treating children with leukemia and lymphoma and conducting research in oncology supportive care, international oncology, and healthcare informatics. He also was the Medical Information Officer and Chief Informaticist for the international outreach programs of St. Jude.

Dr Howard is a former Secretary General for the International Pediatric Oncology Society (SIOP), a former consultant for the World Health Organization (WHO) Global Initiative for Childhood Cancer, and a trustee for the nonprofit World Child Cancer USA. In 2015, he founded Resonance (resonance-health.org), a global organization that provides informatics, consulting, education, and health expertise in hematology/oncology and other domains. Since 2017, Dr Howard has been teaching health economics and epidemiology as Professor at the University of Tennessee Health Science Center. His main research interests include: cancer supportive care, epidemiology, palliative care, and developing cancer programs in low- and middle-income countries. Dr Howard has authored or co-authored 210 scientific papers, 20 book chapters, and a book. He conducts translational and clinical research with collaborators on 5 continents.



Dr Madhumita Dandapani

Dr Madhumita Dandapani received her medical degree from Christian Medical College (Vellore, India) in 2001. She moved to the UK in 2002 and obtained her PhD in cancer cell signalling from the University of Dundee in 2012. She started as a consultant paediatric oncologist at the University of Nottingham, focusing on paediatric solid & brain tumours.

In 2019, Dr Dandapani was appointed as a Clinical Associate Professor of Paediatric Oncology and Neuro-Oncology at Nottingham. Her research and activities focus primarily on developing novel therapies for children with cancer and improving outcomes, particularly in developing countries.

Dr Dandapani also leads a research group at the Nottingham Children's Brain Tumour Research Centre, where she participates in early and late phase clinical trials. She is a member of SIOPEL (International Society of Paediatric Oncology Liver group) and an investigator for the PHITT (Paediatric Hepatic International Tumour Trial). She is also the NIHR CRN lead for paediatric oncology in the East Midlands and principal investigator on several clinical trials.



Dr Caroline Houillier

Dr Caroline Houillier has worked as a neuro-oncologist in the Department of Neurology at the Pitié-Salpêtrière Hospital in Paris since 2008. She has also been the coordinating physician of the French experts network on primary central nervous system (CNS) lymphomas since 2011 (LOC network).

In 2000, she earned her medical degree from Paris VII University Faculté De Médecine Xavier Bichat. She also completed her masters in genetics & biochemistry from Paris VII University and a *Diplôme d'Études Approfondies* (DEA) in neurosciences from Paris VI University. In 2008, Dr Houillier completed her residency and MD in neurology from the Hôpitaux de Paris and Paris VII University, respectively.

Her main research interest is the management of primary CNS lymphoma, which includes usage of CAR-T, targeted & immunotherapy and radiotherapy. For international peer-reviewed journals she has authored/co-authored more than 80 publications, of which 55 are focused on primary CNS lymphoma. Dr Houillier is associated with more than 50 clinical trials in gliomas and primary CNS lymphoma as the principal or co-investigator.

Dr Houillier also serves as a professional member of various neuro-oncological societies, including the Association des Neuro-Oncologues d'Expression Française (ANOCEF), Society of Neuro-oncology (SNO), European Association of Neuro-Oncology (EANO), and EORTC Brain Tumour Group.